Clinical trials: DME, open to volunteers
Diabetic Macular Edema (DME)
Phase 3 Study of Intravitreal OLN324 in Adults With Diabetic Macular Edema (DME) (OLN324-CP-03)
This is a Phase 3 study of an investigational drug called OLN324, which is being developed by Ollin Biosciences as a treatment for patients with diabetic macular edema (DME).
- Trial name
- GOBI (NCT07842016)
- Testing
- OLN324, Aflibercept
- Volunteers
- 450 people
- Sponsor
- Ollin Biosciences, Inc.
Diabetic Macular Edema
A Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of RO7823653 in Participants With Diabetic Macular Edema (DME)
The purpose of this study is to evaluate the safety, tolerability, Pharmacodynamics (PD), and Pharmacokinetics (PK) of multiple doses of RO7823653 in participants with DME, administered by intravitreal (IVT) injection as…
- Trial name
- NCT07425522
- Testing
- RO7823653, Faricimab
- Where
- 12 sites in United States
- Volunteers
- 93 people
- Sponsor
- Genentech, Inc.
Diabetic Macular Edema (DME)
A Phase 3 Trial for Intravitreal Injection of 4D-150 in Adults With Diabetic Macular Edema (DME).
A Phase 3, Randomized, Double-Masked, Active-Controlled Trial to Evaluate the Safety, Efficacy, and Durability of a Single Intravitreal Injection of 4D-150 versus Aflibercept in Adults with Diabetic Macular Edema (4SIGHT)
- Trial name
- 4SIGHT (NCT07867080)
- Testing
- 4D-150 IVT (3x10^10 vg), EYELEA ® (aflibercept) Injection 2 mg (0.05mL)
- Where
- 92 sites in United States, China and 2 more
- Volunteers
- 514 people
- Sponsor
- 4D Molecular Therapeutics
Early OCT Biomarker Changes in Response to Anti-VEGF
Early Changes in OCT Biomarkers After the First Intravitreal Anti-VEGF Injection in Treatment-naïve DME
A retrospective, observational, hospital-based study which will be conducted in the Department of Ophthalmology, Sohag University Hospital, Egypt.
- Trial name
- NCT06841250
- Testing
- intravitreal injection of anti-VEGF
- Where
- Egypt
- Volunteers
- 50 people
- Sponsor
- Sohag University
nAMD, DME
Real-World Study of Intravitreal Aflibercept 8 mg in Pretreated Eyes With nAMD or DME
The goal of this multicentre observational study is to evaluate the interval-extension potential, effectiveness, and safety of intravitreal aflibercept 8 mg in pretreated eyes with neovascular age-related macular degeneration…
- Trial name
- ALLEVI8 (NCT07761039)
- Testing
- Aflibercept 8mg
- Volunteers
- 100 people
- Sponsor
- Grupo de Estudos da Retina
Diabetic Macular Edema, Macular Edema
MS-553 in Diabetic Retinopathy Patients With Central Involved Macular Edema
This is an open label dose-escalation study to evaluate the safety and treatment benefits of MS-553 in treatment-naive diabetic retinopathy patients with central involved macular edema.
- Conditions
- Diabetic Macular Edema, Macular Edema, Type 2 Diabetes With Diabetic Macular Edema, Type 1 Diabetes With Diabetic Macular Edema
- Trial name
- NCT04187443
- Testing
- MS-553
- Where
- 3 sites in China
- Volunteers
- 45 people
- Sponsor
- Shenzhen MingSight Relin Pharmaceuticals Co., Ltd.
Diabetic Macular Edema, Visual Impairment
Evaluation of Serum- and OCT Biomarkers in Patients With DME Treated With Anti-VEGF or Dexamethasone Implant
This study aims to investigate the association between serum biomarkers and clinical response to anti-VEGF or dexamethasone implant by assessing OCT-biomarkers in patients with diabetic macular edema, DME, and to compare these…
- Conditions
- Diabetic Macular Edema, Visual Impairment, Diabetes Mellitus, Hyperglycaemia (Diabetic)
- Trial name
- BiomarkerOCT (NCT06984822)
- Testing
- Anti-VEGF treatment, Dexamethasone implant, Treatment with intravitreal anti-VEGF OR Dexamethasone implant
- Where
- 2 sites in Sweden
- Volunteers
- 150 people
- Sponsor
- Vastra Gotaland Region
Diabetic Macular Edema (DME)
A First-in-human Trial of SZN-8141 in Diabetic Macular Edema
DUET (Cl-8141-1001) is a first-in-human clinical trial evaluating the safety, tolerability, pharmacokinetics (how the body processes the study drug), and preliminary biological activity of SZN-8141 in people with diabetic macular…
- Trial name
- DUET (NCT07817121)
- Testing
- SZN-8141 for Injection
- Volunteers
- 9 people
- Sponsor
- Surrozen Operating, Inc.
DME, Retinal Vein Occlusion (RVO)
AI vs. Physician for Anti-VEGF Decision-Making: An RCT
We developed an artificial intelligence system, called QiLin, which was designed to assist anti-VEGF treatment decisions in retinal diseases.
- Conditions
- DME, Retinal Vein Occlusion (RVO), Neovascular (Wet) Age-Related Macular Degeneration
- Trial name
- NCT07328776
- Testing
- QiLin-assisted, physician only, without QiLin assisted
- Where
- 2 sites in China
- Volunteers
- 200 people
- Sponsor
- Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
DME, Dental
Clinical Performance of High Viscosity Bioactive Injectable Composite in Deep Marginal Elevation
Using a bioactive resin composite in subgingival Class II cavities can provide enhanced caries resistance by releasing multiple ions, including fluoride.
- Conditions
- DME, Dental, Deep Margin Elevation
- Trial name
- Randomized (NCT06875544)
- Testing
- Beautifil F00, G-aenial Universal Injectable Flowable Composite
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Future University in Egypt
Diabetic Macular Edema (DME)
Safety and Efficacy Evaluation of LX111 Gene Therapy in DME Patients
The goal of this study is to evaluate the safety and efficacy of LX111 treatment of DME. This study will enroll participants aged ≥ 18 vears old to receive a single unilateral intravitreal (lVT) injection of LX111 to evaluate its…
- Trial name
- NCT07362927
- Testing
- LX111 Injection
- Where
- 2 sites in China
- Volunteers
- 32 people
- Sponsor
- Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Deep Marginal Elevation, Periodontal Microenvironment
Deep Marginal Elevation and the Periodontal Microenvironment ( DME-PM )
This study aims to evaluate the impact of the dental restorative procedure known as Deep Marginal Elevation (DME) on periodontal health, including gingival and bone status, in patients with deep dental caries.
- Conditions
- Deep Marginal Elevation, Periodontal Microenvironment, Microbiological Study, Clinical Study
- Trial name
- NCT07156695
- Testing
- Deep Marginal Elevation (DME)
- Where
- Egypt
- Volunteers
- 36 people
- Sponsor
- Tanta University
Diabetic Retinopathy, Macular Edema
A Clinical Trial of MK-8748 Compared to Aflibercept in Participants With Diabetic Macular Edema (MK-8748-004)
Researchers are looking for new ways to treat diabetic macular edema (DME). In this trial, researchers want to learn if a trial medicine called MK-8748 can treat DME.
- Trial name
- NCT07705555
- Testing
- MK-8748, Aflibercept
- Where
- 35 sites in United States, Argentina and 2 more
- Volunteers
- 960 people
- Sponsor
- Merck Sharp & Dohme LLC
Diabetic Retinopathy (DR), Diabetic Macular Edema (DME)
Comparing Single Versus Multiple Anti-VEGF Injections in Diabetic Patients Undergoing Cataract Surgery
Objective of this randomised controlled trial is to compare the efficacy of a single per operative anti VEGF injection with repeated postoperative anti VEGF injections in the prevention of diabetic retinopathy progression after…
- Conditions
- Diabetic Retinopathy (DR), Diabetic Macular Edema (DME), Cataract, Phacoemulfisication+IOL Implantation
- Trial name
- NCT07301775
- Testing
- Aflibercept (Eylea)
- Where
- 2 sites in Pakistan
- Volunteers
- 166 people
- Sponsor
- Ahmad Zeeshan Jamil
Diabetic Macular Edema (DME)
A Study to Evaluate the Efficacy and Safety of Tabirafusp Tedromer Compared to Aflibercept in Participants With DME - ALTO
A Study to Evaluate the Efficacy and Safety of Tabirafusp Tedromer Compared to Aflibercept in Participants with Diabetic Macular Edema - ALTO
- Trial name
- ALTO (NCT07734844)
- Testing
- Tabirafusp tedromer, Aflibercept (2.0 mg)
- Where
- 52 sites in United States, Argentina
- Volunteers
- 910 people
- Sponsor
- Kodiak Sciences Inc
Neovascular Age-related Macular Degeneration (nAMD), Diabetic Macular Edema (DME)
A Phase I Study of GenSci148 Intravitreal Injection for Neovascular Age-related Macular Degeneration, Diabetic Macular Edema and Retinal Vein Occlusion
This is a Phase I, multicenter, open-label, dose-escalation study conducted in two parts to evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of GenSci148 administered via intravitreal (IVT)…
- Conditions
- Neovascular Age-related Macular Degeneration (nAMD), Diabetic Macular Edema (DME), Retinal Vein Occlusion (RVO)
- Trial name
- GenSci148-101 (NCT07817615)
- Testing
- GenSci148 Injection
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.
Deep Margin Elevation, Pulpal and Periodontal Health
Impact of DME on Pulpal and Periodontal Health at Varying Gingival Seat Level
The classical idea was to keep the biologic width untouched in order to maintain periodontal health but the newer case reports have given a new dimension to this concept, stating that a limited extension into STA can be used as…
- Trial name
- NCT07169305
- Testing
- Deep Margin Elevation
- Where
- India
- Volunteers
- 81 people, healthy volunteers welcome
- Sponsor
- Postgraduate Institute of Dental Sciences Rohtak
Diabetic Retinopathy
Surabgene Lomparvovec Administered in the Suprachoroidal Space in Adult Participants With Diabetic Retinopathy Without Center-Involved Diabetic Macular Edema
Diabetic Retinopathy (DR) is a common eye condition caused by diabetes, where high blood sugar levels damage the blood vessels in the back part of the eye (called the retina).
- Trial name
- NAAVIGATE (NCT07592273)
- Testing
- Surabgene Lomparvovec, Topical Steroid, Artificial Tears
- Where
- 40 sites in United States, Puerto Rico
- Volunteers
- 576 people
- Sponsor
- AbbVie
Age-Related Macular Degeneration (AMD), Diabetic Macular Edema (DME)
Study of JMKX003948 Ophthalmic Suspension in Healthy Participants
The study is a randomized, double-blind, placebo-controlled, phase 1 study of JMKX003948 Ophthalmic Suspension to evaluate the safety, tolerability and PK of single and multiple ascending doses in healthy participants.
- Trial name
- NCT06832657
- Testing
- JMKX003948 Ophthalmic Suspension
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Jemincare
Diabetic Macular Edema
Kamuvudine-9 (K9) in Diabetic Macular Edema
The objectives of this investigation are to assess: 1. whether oral K9 is safe in subjects with DME, and 2. whether oral K9 improves BCVA compared to oral placebo
- Trial name
- K9 (NCT07458061)
- Testing
- Kamuvudine K9
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Dr. Bryan Strelow